Serina Therapeutics, Inc. Stock Issued During Period, Value, Restricted Stock Award, Gross
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Serina Therapeutics, Inc. stock issued during period, value, restricted stock award, gross for the quarter ending 2025-06-30 was $29.00K.
- Serina Therapeutics, Inc. stock issued during period, value, restricted stock award, gross for the quarter ending 2023-12-31 was $0.00.
- Serina Therapeutics, Inc. stock issued during period, value, restricted stock award, gross for the quarter ending 2023-09-30 was $0.00.
- Serina Therapeutics, Inc. stock issued during period, value, restricted stock award, gross for the quarter ending 2023-06-30 was $0.00.
- Serina Therapeutics, Inc. stock issued during period, value, restricted stock award, gross for fiscal 2025 was $29.00K.
- Serina Therapeutics, Inc. stock issued during period, value, restricted stock award, gross for fiscal 2023 was -$1.00K.
- Serina Therapeutics, Inc. stock issued during period, value, restricted stock award, gross for fiscal 2022 was -$4.00K.
- Serina Therapeutics, Inc. stock issued during period, value, restricted stock award, gross for fiscal 2021 was -$7.00K.
| Period end | Stock Issued During Period, Value, Restricted Stock Award, Gross 3 month | Stock Issued During Period, Value, Restricted Stock Award, Gross 12 month |
|---|---|---|
| 2025-12-31 | $29.00K 10-K · filed 2026-03-25 | |
| 2025-06-30 | $29.00K 10-Q · filed 2026-08-13 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | -$1.00K 10-K · filed 2024-03-22 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$2.00K derived: sum of 4 quarters · filed 2024-03-22 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$3.00K derived: sum of 4 quarters · filed 2024-03-22 |
| 2023-03-31 | -$1.00K 10-Q · filed 2023-05-12 | -$4.00K derived: sum of 4 quarters · filed 2024-03-22 |
| 2022-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | -$4.00K 10-K · filed 2024-03-22 |
| 2022-09-30 | -$1.00K 10-Q · filed 2023-11-14 | -$4.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$1.00K 10-Q · filed 2023-08-14 | -$4.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$1.00K 10-Q · filed 2023-05-12 | -$5.00K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$7.00K 10-K · filed 2023-03-31 |
| 2021-09-30 | -$1.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$2.00K 10-Q · filed 2022-08-12 | |
| 2021-03-31 | -$3.00K 10-Q · filed 2022-05-13 | |
| 2020-12-31 | -$9.00K 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |